Pharmaxis Faces New Study Requirement For CF Drug Bronchitol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a “complete response” letter, FDA says efficacy has not been adequately demonstrated for use of dry powder mannitol in cystic fibrosis patients ages six years and older.